A minimally invasive therapy that has the potential to transform treatment of a common cause of high blood pressure, has been developed by researchers at UCL, Queen Mary University of London and Barts Health.
European regulators consider appeal over Amylyx ALS drug
LONDON — This week, European regulators are considering an appeal from Amylyx Pharmaceuticals after initially recommending against approving the company’s ALS treatment — the latest
October 11, 2023